Tardive dyskinesia (TD) is a potentially irreversible movement disorder related to chronic antipsychotic medication exposure. The etiology is unknown, though genetic factors are likely contributors. 1 Although the dopamine D 2 receptor has been recognized as the main target for antipsychotics, studies investigating potential involvement of D 2 gene (DRD2) polymorphisms in TD have yielded mixed results. 2 Of these polymorphisms, TaqIA and À141C Ins/Del, have been studied most extensively.
The À141C Del allele has been reported to decrease DRD2 promoter activity in vitro, while two in vivo studies showed the Del allele to be associated either with an increase in striatal D 2 binding or with no significant difference. 2 The Taq1A polymorphism was recently discovered to reside in the coding region of an overlapping gene coding for a serine/threonine kinase, and cause an amino-acid change. 2 However, the A1 (T) allele has been associated with reduced D 2 levels in most reported studies. 2 We carried out a computer search on the National Library of Medicine's PubMed online search engine database for all papers published up to December 2006 on 'tardive dyskinesia' and 'DRD2'. In all, 12 genetic association studies were found reporting on TD and DRD2. Six included the number of patients with and without TD and genotypes for Taq1A, while five included the number of TD-positive and TD-negative patients with genotypes for the À141C Ins/Del polymorphism. [2] [3] [4] [5] [6] [7] [8] All subjects were selected based on their diagnoses of schizophrenia or schizoaffective disorder, according to DSM-III-R or IV, using case records with or without patient interviews. The presence of TD was assessed from our study using the Abnormal Involuntary Movement Scale (AIMS) or the modified Hillside Simpson Dyskinesia Scale (HSDS) in the case of 49 patients, as described previously.
2 TD ratings were performed once for the majority of the studies. Quantitative AIMS scores were not available for most subjects and were not included in the analyses (Table 1) .
In all, 1256 schizophrenia patients were genotyped for Taq1A. Of them, 507 were positive for the diagnosis of TD. A total of 897 schizophrenia patients were genotyped for À141C Ins/Del, of which 328 were TD positive.
We analysed the data using the Stata statistical software package (StataCorp 2003, Stata Statistical Software: Release 8. College Station, TX: StataCorp LP). The odds ratios and standard errors of Taq1A and À141C I/D for TD were calculated from the individual studies using the 'metan' command, with the pooled odds ratio and standard error calculated under the random effects model. The possible effects of ethnicity, age, and gender ratio on heterogeneity among the studies were assessed by meta-regression analysis using the 'metareg' command. We tested for publication bias using the 'metabias' command. Compared to TD-negative patients, TD-positive patients had a higher A2 allele frequency (P = 0.003), with an effect-size of 1.30 (95% CI: 1.09-1.55), and higher A2/A2 genotype frequency (P = 0.001), with an effect-size of 1.50 (95% CI: 1.17-1.92). The À141C Ins/Del alleles and genotypes were not associated with TD. There was no evidence of heterogeneity among the studies or publication bias for Taq1A or À141C Ins/Del (P > 0.1). Ethnicity, gender ratio, or age did not contribute to the results observed for Taq1A (P > 0.1).
Despite heterogeneity amongst studies in terms of TD assessment, results from the present meta-analysis suggest that Taq1A is associated with TD and are in agreement with two of the previous studies. 4, 9 The mixed results in other studies could be attributed to the lower A1 allele frequencies observed in European Caucasians compared to East Asians, as well as to small sample sizes. The results reported here could be affected by potential confounding factors, including tobacco and substance use, antipsychotic dose, and years of antipsychotic exposure, information that was not available for most of the studies. False-positive results from multiple testing are possible, but association between Taq1A and TD from the present metaanalysis would have survived correction for testing two markers.
The relatively low OR is consistent with the idea of contributions of multiple genetic variants in complex phenotypes, with DRD3 Ser9Gly as an example of another genetic risk factor for TD. 9 Nonetheless, the present study, the first meta-analysis of DRD2 polymorphisms in TD, encourages further examination of the role of Taq1A in TD. A recent meta-analysis of association findings for DAOA suggests that multiple risk polymorphisms within the gene are contributing to schizophrenia susceptibility. 1 Specifically, this meta-analysis identified association with single nucleotide polymorphisms (SNPs) downstream of the 3 0 end of the gene (rs3918342 (M23) and rs1421292 (M24)) and with SNPs at the 5 0 end of the gene (rs3916965 (M12) in the putative promoter region and rs2391191 (M15) in exon 2). In addition to being one of the most strongly associated markers in the meta-analysis, M15 is also a putative functional polymorphism causing an arginine-to-lysine substitution at codon 30 (ARG30LYS). The functional impact of this substitution has yet to be determined. Following a recent association between cognitive deficits and M24 at DAOA, 2 we investigated whether the ARG30LYS substitution was also associated with cognitive impairments. We reasoned that such evidence would provide important support for the role of this putative functional polymorphism in brain activity.
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After receiving ethical approval, we collected neuropsychological assessments on a subset of 93 consenting patients with DSM-IV schizophrenia from our total case control sample (comprised of 373 cases and 812 controls, all of Irish nationality). All patients were clinically stable, aged between 18 and 60 years, and were free from confounding factors such as epilepsy, substance abuse or acquired brain injury. This subgroup had a mean age of 46.2 years (s.d. = 9.3), was comprised primarily of males (75%) and had a predominantly chronic illness history (duration in years 22.3710.4; range 4-42).
